Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock.

A number of other equities research analysts have also weighed in on HUMA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 15th. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday. Benchmark decreased their price target on shares of Humacyte from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. Finally, BTIG Research restated a “buy” rating and set a $6.00 price objective on shares of Humacyte in a report on Friday, November 21st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.29.

Humacyte Price Performance

HUMA opened at $1.13 on Monday. The business has a fifty day moving average of $1.37 and a 200 day moving average of $1.78. The stock has a market cap of $211.62 million, a P/E ratio of -4.91 and a beta of 1.90. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97. Humacyte has a 52-week low of $1.04 and a 52-week high of $5.66.

Humacyte (NASDAQ:HUMA) last released its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.92 million. As a group, sell-side analysts anticipate that Humacyte will post -1.27 EPS for the current year.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently bought and sold shares of HUMA. Polar Asset Management Partners Inc. purchased a new stake in Humacyte during the first quarter valued at approximately $852,000. Woodline Partners LP increased its position in shares of Humacyte by 38.7% during the first quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock worth $6,735,000 after purchasing an additional 1,101,198 shares in the last quarter. Nuveen LLC acquired a new position in shares of Humacyte during the first quarter worth $502,000. CenterBook Partners LP lifted its holdings in shares of Humacyte by 141.1% during the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after purchasing an additional 2,007,743 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new stake in shares of Humacyte in the 1st quarter worth $5,648,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.